PMID- 30908073
OWN - NLM
STAT- MEDLINE
DCOM- 20190423
LR  - 20190423
IS  - 0894-203X (Print)
IS  - 0894-203X (Linking)
VI  - 35
IP  - 1
DP  - 2019 Jan
TI  - Serologic problems associated with administration of intravenous immune globulin 
      (IVIg).
PG  - 13-15
AB  - Intravenous immune globulin (IVIg) is manufactured from large pools of donor 
      plasma and contains a high diversity of antibodies, primarily IgG. For this 
      reason, IVIg is routinely used as antibody replacement therapy for patients 
      having primary immunodeficiencies. In 1981, IVIg was also found to be a strong 
      immunomodulator of various inflammatory and autoimmune conditions. This 
      observation has led to the exponential increase in the use of IVIg throughout the 
      world, with the United States and Canada being the biggest users of IVIg. 
      Although relatively rare, adverse events, such as hemolytic anemia and 
      thrombosis, can complicate the administration of IVIg. More frequently, the 
      administration of IVIg can cause serologic challenges for the transfusion service 
      including ABO discrepancies, positive direct antiglobulin tests, positive 
      antibody detection tests, and incompatible crossmatches. This article will review 
      each of the potential transfusion service challenges associated with IVIg 
      administration.
FAU - Branch, Donald R
AU  - Branch DR
AD  - Departments of Medicine and Laboratory Medicine and Pathobiology, University of 
      Toronto, Division of Experimental Therapeutics, Toronto General Hospital Research 
      Institute, University Health Network, and the Centre for Innovation, Canadian 
      Blood Services.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Immunohematology
JT  - Immunohematology
JID - 8806387
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Canada
MH  - Coombs Test
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/*therapeutic use
EDAT- 2019/03/26 06:00
MHDA- 2019/04/24 06:00
CRDT- 2019/03/26 06:00
PHST- 2019/03/26 06:00 [entrez]
PHST- 2019/03/26 06:00 [pubmed]
PHST- 2019/04/24 06:00 [medline]
PST - ppublish
SO  - Immunohematology. 2019 Jan;35(1):13-15.